Você procurou por: kimoterapewtiċi (Maltês - Inglês)

kimoterapewtiċi
chemotherapeutics

sustanzi kimoterapewtiċi
chemotherapeutic agents

mediċini kimoterapewtiċi:
chemotherapeutic agents:

prodotti mediċinali kimoterapewtiċi
chemotherapeutic medicinal products

sustanzi kimoterapewtiċi li huma substrati għal cyp3a4
chemotherapeutic agents that are substrates for cyp3a4

vectibix flimkien ma ’ bevacizumab u korsijiet kimoterapewtiċi
vectibix in combination with bevacizumab and chemotherapy regimens

prodotti mediċinali kimoterapewtiċi (docetaxel, etoposide, cyclophosphamide)
chemotherapeutic medicinal products (docetaxel, etoposide, cyclophosphamide)

bħal sustanzi kimoterapewtiċi oħrajn, hija rakkomandata kawtela sabiex tkun evitata l-estravażjoni.
as with other similar chemotherapeutic agents, caution is recommended to avoid extravasation.

l-anemija kienet komunement ħafna irrapportata meta mifamurtide jintuża flimkien ma’ mediċini kimoterapewtiċi.
anaemia has very commonly been reported when mifamurtide is used in conjunction with chemotherapeutic agents.

għandha tingħata attenzjoni speċjali meta tagħti mediċini kimoterapewtiċi waħidhom jew flimkien, li hu magħruf li jikkawżaw tromboċitopenja severa.
special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.

għaldaqstant, l-użu ta’ imatinib kombinat ma’ mediċini kimoterapewtiċi oħrajn jeħtieġ kawtela speċjali.
therefore, the use of imatinib in combination with other chemotherapeutic agents requires special precaution.

għandu jkun hemm attenzjoni speċjali meta tingħata sustanza kimoterapewtika waħda jew taħlita ta’ sustanzi kimoterapewtiċi li huma magħrufa li jikkawżaw tromboċitopenija severa.
special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.

il-kawtela speċjali trid tiġi eżerċitata meta sustanzi kimoterapewtiċi, magħrufin li jistgħu jwasslu għal tromboċitopenja qawwija, jiġu amministrati jew waħidhom inkella flimkien.
special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.

madankollu, huwa rrakkomandat li mabcampath m’għandux jingħata fi żmien 3 ġimgħat wara t-teħid ta’ sustanzi kimoterapewtiċi oħra.
however, it is recommended that mabcampath should not be given within 3 weeks of other chemotherapeutic agents.

is severità tal-ġrajjiet avversi ta’ docetaxel tista’ tiżdied meta docetaxel jingħata flimkien ma’ sustanzi kimoterapewtiċi oħra.
the severity of adverse events of docetaxel may be increased when docetaxel is given in combination with other chemotherapeutic agents.

is-severità ta’ każijiet avversi b’ docetaxel mylan jistgħu jiżdiedu meta docetaxel mylan jingħata flimkien ma’ sustanzi kimoterapewtiċi oħra.
the severity of adverse events of docetaxel mylan may be increased when docetaxel mylan is given in combination with other chemotherapeutic agents.

is-severità ta’ dawn il-ġrajjiet avversi ta’ taxotere jistgħu jiżdiedu meta taxotere jingħata flimkien ma’ sustanzi kimoterapewtiċi oħra.
the severity of adverse events of taxotere may be increased when taxotere is given in combination with other chemotherapeutic agents.

11 każijiet ta ’ insuffiċjenza renali akuta ġew irrapportati meta ntuża pemetrexed waħdu jew flimkien ma ’ sustanzi kimoterapewtiċi oħra (ara sezzjoni 4. 4).
cases of acute renal failure have been reported with pemetrexed alone or in association with other chemotherapeutic agents (see section 4.4).

l-għoti flimkien ta’ depocyte ma’ mediċini kimoterapewtiċi newrotossiċi oħrajn jew ma’ irradjazzjoni kranjali/tas-sinsla tad-dahar jista’ jżid ir-riskju ta’ newrotossiċità.
administration of depocyte in combination with other neurotoxic chemotherapeutic agents or with cranial/spinal irradiation may increase the risk of neurotoxicity.